These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 32669350)
1. A Novel Mechanism to Induce BRCAness in Cancer Cells. Cai C Cancer Res; 2020 Jul; 80(14):2977-2978. PubMed ID: 32669350 [TBL] [Abstract][Full Text] [Related]
2. Crosstalk of DNA double-strand break repair pathways in poly(ADP-ribose) polymerase inhibitor treatment of breast cancer susceptibility gene 1/2-mutated cancer. Sunada S; Nakanishi A; Miki Y Cancer Sci; 2018 Apr; 109(4):893-899. PubMed ID: 29427345 [TBL] [Abstract][Full Text] [Related]
3. Inactivation of the Prolyl Isomerase Pin1 Sensitizes BRCA1-Proficient Breast Cancer to PARP Inhibition. Luo ML; Zheng F; Chen W; Liang ZM; Chandramouly G; Tan J; Willis NA; Chen CH; Taveira MO; Zhou XZ; Lu KP; Scully R; Wulf GM; Hu H Cancer Res; 2020 Jul; 80(14):3033-3045. PubMed ID: 32193285 [TBL] [Abstract][Full Text] [Related]
5. Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides Voutsadakis IA; Stravodimou A Anticancer Res; 2023 Mar; 43(3):967-981. PubMed ID: 36854505 [TBL] [Abstract][Full Text] [Related]
6. Exploiting replication gaps for cancer therapy. Cong K; Cantor SB Mol Cell; 2022 Jul; 82(13):2363-2369. PubMed ID: 35568026 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic targeting and patient selection for cancers with homologous recombination defects. Talens F; Jalving M; Gietema JA; Van Vugt MA Expert Opin Drug Discov; 2017 Jun; 12(6):565-581. PubMed ID: 28425306 [TBL] [Abstract][Full Text] [Related]
8. BRCAness, Homologous Recombination Deficiencies, and Synthetic Lethality. Murai J; Pommier Y Cancer Res; 2023 Apr; 83(8):1173-1174. PubMed ID: 37057596 [TBL] [Abstract][Full Text] [Related]
9. DNA repair and cell cycle checkpoint defects in a mouse model of 'BRCAness' are partially rescued by 53BP1 deletion. Misenko SM; Patel DS; Her J; Bunting SF Cell Cycle; 2018; 17(7):881-891. PubMed ID: 29620483 [TBL] [Abstract][Full Text] [Related]
10. Advances in PARP inhibitors for the treatment of breast cancer. Dizdar O; Arslan C; Altundag K Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111 [TBL] [Abstract][Full Text] [Related]
11. Shaping the BRCAness mutational landscape by alternative double-strand break repair, replication stress and mitotic aberrancies. Stok C; Kok YP; van den Tempel N; van Vugt MATM Nucleic Acids Res; 2021 May; 49(8):4239-4257. PubMed ID: 33744950 [TBL] [Abstract][Full Text] [Related]
13. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Helleday T Mol Oncol; 2011 Aug; 5(4):387-93. PubMed ID: 21821475 [TBL] [Abstract][Full Text] [Related]
14. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside. Turk AA; Wisinski KB Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759 [TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of PARP inhibitors in breast cancer. Pandya K; Scher A; Omene C; Ganesan S; Kumar S; Ohri N; Potdevin L; Haffty B; Toppmeyer DL; George MA Breast Cancer Res Treat; 2023 Jul; 200(1):15-22. PubMed ID: 37129747 [TBL] [Abstract][Full Text] [Related]
16. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy]. Schreiber V; Illuzzi G; Héberlé E; Dantzer F Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693 [TBL] [Abstract][Full Text] [Related]
17. Tumor Intrinsic PD-L1 Promotes DNA Repair in Distinct Cancers and Suppresses PARP Inhibitor-Induced Synthetic Lethality. Kornepati AVR; Boyd JT; Murray CE; Saifetiarova J; de la Peña Avalos B; Rogers CM; Bai H; Padron AS; Liao Y; Ontiveros C; Svatek RS; Hromas R; Li R; Hu Y; Conejo-Garcia JR; Vadlamudi RK; Zhao W; Dray E; Sung P; Curiel TJ Cancer Res; 2022 Jun; 82(11):2156-2170. PubMed ID: 35247877 [TBL] [Abstract][Full Text] [Related]
18. Resurrection of PARP Inhibitors in Breast Cancer. Lyons TG; Robson ME J Natl Compr Canc Netw; 2018 Sep; 16(9):1150-1156. PubMed ID: 30181424 [TBL] [Abstract][Full Text] [Related]
19. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. Watkins JA; Irshad S; Grigoriadis A; Tutt AN Breast Cancer Res; 2014 Jun; 16(3):211. PubMed ID: 25093514 [TBL] [Abstract][Full Text] [Related]
20. A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells. Senhaji Mouhri Z; Goodfellow E; Jean-Claude B BMC Cancer; 2017 Aug; 17(1):540. PubMed ID: 28800752 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]